Abstract
Evidence of high efficacy of live attenuated influenza vaccine (LAIV) from randomized controlled trials is strong for children 2-6 years of age, but fewer data exist for older school-age children. We reviewed the published data on efficacy and effectiveness of LAIV in children ≥5 years. QUOSA (Elsevier database) was searched for articles published from January 1990 to June 2014 that included FluMist, LAIV, CAIV, cold adapted influenza vaccine, live attenuated influenza vaccine, live attenuated cold adapted or flu mist. Studies evaluated included randomized controlled trials, effectiveness and indirect protection studies. This review demonstrates that LAIV has considerable efficacy and effectiveness in school-age children.
Original language | English (US) |
---|---|
Pages (from-to) | 1331-1346 |
Number of pages | 16 |
Journal | Expert Review of Vaccines |
Volume | 14 |
Issue number | 10 |
DOIs | |
State | Published - Oct 3 2015 |
Funding
This study was sponsored by MedImmune. R Olajide is an employee of AstraZeneca, the parent company of MedImmune. K Coelingh and P MacDonald are former employees of MedImmune. R Yogev is on the speakers bureau for MedImmune. The authors thank C Ambrose and H Caspard (MedImmune) for review of the manuscript and helpful comments and D Swanson (AstraZeneca) for assistance with manuscript preparation. Medical writing assistance, including developing a first draft based on an outline developed by the authors, editing and formatting the manuscript, and collating and incorporating the authors’ comments, was provided by AS Wu, JE Fincke and C Lundin of Complete Healthcare Communications, Inc. (Chadds Ford, PA) and funded by AstraZeneca. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Keywords
- effectiveness
- efficacy
- influenza vaccine
- live attenuated influenza vaccine
- school-age children
ASJC Scopus subject areas
- Drug Discovery
- Molecular Medicine
- Pharmacology
- Immunology